Alphamab Oncology, 3DMed start Phase II of PD-L1 antibody in solid tumors

Alphamab Oncology (Suzhou, China) and 3D Medicines Corp. (Shanghai, China) began a Phase II trial of KN035 in previously-treated patients with locally advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma and other solid tumors.

The open-label, Chinese trial will enroll about 110 patients. The trial's primary endpoint is objective response rate (ORR). ...